茚达特罗的药理学特点及临床评价研究进展  

Pharmacology and clinical evaluation of indacaterol

作　　者：王丹丹[1] 孙铁英[1] 

机构地区：[1]卫生部北京医院呼吸与危重症医学科,北京100730

出　　处：《中国新药杂志》2013年第1期1-3,22,共4页Chinese Journal of New Drugs

摘　　要：慢性阻塞性肺疾病(COPD)的发病率和死亡率正逐渐增高,并且已成为全球的一个主要健康问题,但在过去几十年中关于它的药物治疗进展却很缓慢。β2-肾上腺素能受体激动剂可以改善COPD患者症状,是主要治疗药物。茚达特罗是一种新型长效β2-肾上腺素能受体激动剂,临床用于中重度COPD患者稳定期的维持治疗。其起效迅速、作用持续时间长,每日只需给药1次。大规模临床研究显示茚达特罗可以明显改善患者第1秒用力呼气容积(FEV1),减少COPD急性发作,改善呼吸困难症状,提高生活质量,并具有良好的耐受性,为COPD的治疗提供新的选择。Although chronic obstructive pulmonary disease（COPD） is a major global health problem with a rising incidence and morbidity,few pharmacotherapeutic advances have been made over the past several decades.Indacaterol is a novel long-acting β2-adrenoceptor agonist that is available for the maintenance treatment of airflow obstruction in adult COPD patients.The onset of bronchodilation after inhalation of indacaterol is fast.Indacaterol has a 24-h bronchodilatory effect,which allows for once-daily administration.In some large-scale clinical trials,patients who received indacaterol had a significantly higher mean trough forced expiratory volume in 1 second（FEV1） than placebo recipients.COPD exacerbations and symptoms,and health-related quality of life were also significantly improved.Indacaterol was generally well tolerated.It is a new choice for the treatment of COPD.

关 键 词：茚达特罗 慢性阻塞性肺疾病 Β2受体激动剂 药理学 药代动力学 

分 类 号：R974[医药卫生—药品]